References

References

1. Eaton EF, Kulczycki A, Saag M, Mugavero M, Raper JL. Immunization costs and programmatic barriers at an urban HIV clinic. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2015;61(11):1726-31.
2. Geretti AM, Doyle T. Immunization for HIV-positive individuals. Current opinion in infectious diseases. 2010;23(1):32-8.
3. Slim J, Saling CF. A Review of Management of Inflammation in the HIV Population. BioMed research international. 2016;2016:3420638.
4. Tan DH, Szadkowski L, Raboud J, Yi TJ, Shannon B, Kaul R, et al. Effect of Intercurrent Infections and Vaccinations on Immune and Inflammatory Biomarkers Among Human Immunodeficiency Virus-Infected Adults on Suppressive Antiretroviral Therapy. Open forum infectious diseases. 2015;2(2):ofv036.
5. Nicolini LA, Giacobbe DR, Di Biagio A, Viscoli C. Insights on common vaccinations in HIV-infection: efficacy and safety. J Prev Med Hyg. 2015;56(1):E28-32.
6. Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS medicine. 2008;5(10):e203.
7. Crum-Cianflone NF, Wallace MR. Vaccination in HIV-infected adults. AIDS patient care and STDs. 2014;28(8):397-410.
8. Kerneis S, Launay O, Turbelin C, Batteux F, Hanslik T, Boelle PY. Long-term immune responses to vaccination in HIV-infected patients: a systematic review and meta-analysis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2014;58(8):1130-9.
9. Ceravolo A, Orsi A, Parodi V, Ansaldi F. Influenza vaccination in HIV-positive subjects: latest evidence and future perspective. J Prev Med Hyg. 2013;54(1):1-10.
10. Remschmidt C, Wichmann O, Harder T. Influenza vaccination in HIV-infected individuals: systematic review and assessment of quality of evidence related to vaccine efficacy, effectiveness and safety. Vaccine. 2014;32(43):5585-92.
11. Cohen C, Moyes J, Tempia S, Groome M, Walaza S, Pretorius M, et al. Mortality amongst patients with influenza-associated severe acute respiratory illness, South Africa, 2009-2013. PloS one. 2015;10(3):e0118884.
12. Cohen C, Walaza S, Moyes J, Groome M, Tempia S, Pretorius M, et al. Epidemiology of severe acute respiratory illness (SARI) among adults and children aged >/=5 years in a high HIV-prevalence setting, 2009-2012. PloS one. 2015;10(2):e0117716.
13. Cohen C, Moyes J, Tempia S, Groom M, Walaza S, Pretorius M, et al. Severe influenza-associated respiratory infection in high HIV prevalence setting, South Africa, 2009-2011. Emerging infectious diseases. 2013;19(11):1766-74.
14. Kroon FP, van Dissel JT, de Jong JC, Zwinderman K, van Furth R. Antibody response after influenza vaccination in HIV-infected individuals: a consecutive 3-year study. Vaccine. 2000;18(26):3040-9.
15. Madhi SA, Maskew M, Koen A, Kuwanda L, Besselaar TG, Naidoo D, et al. Trivalent inactivated influenza vaccine in African adults infected with human immunodeficient virus: double blind, randomized clinical trial of efficacy, immunogenicity, and safety. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2011;52(1):128-37.
16. Madhi SA, Nunes MC, Cutland CL. Influenza vaccination of pregnant women and protection of their infants. The New England journal of medicine. 2014;371(24):2340.
17. McAnerney JM, Cohen C, Moyes J, Besselaar TG, Buys A, Schoub BD, et al. Twenty-five years of outpatient influenza surveillance in South Africa, 1984-2008. The Journal of infectious diseases. 2012;206 Suppl 1:S153-8.
18. Cohen C, Naidoo N, Meiring S, de Gouveia L, von Mollendorf C, Walaza S, et al. Streptococcus pneumoniae Serotypes and Mortality in Adults and Adolescents in South Africa: Analysis of National Surveillance Data, 2003 - 2008. PloS one. 2015;10(10):e0140185.
19. French N, Gordon SB, Mwalukomo T, White SA, Mwafulirwa G, Longwe H, et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. The New England journal of medicine. 2010;362(9):812-22.
20. Lombardi F, Belmonti S, Fabbiani M, Morandi M, Rossetti B, Tordini G, et al. Immunogenicity and Safety of the 13-Valent Pneumococcal Conjugate Vaccine versus the 23-Valent Polysaccharide Vaccine in Unvaccinated HIV-Infected Adults: A Pilot, Prospective Controlled Study. PloS one. 2016;11(6):e0156523.
21. Meiring S, Cohen C, Quan V, de Gouveia L, Feldman C, Karstaedt A, et al. HIV Infection and the Epidemiology of Invasive Pneumococcal Disease (IPD) in South African Adults and Older Children Prior to the Introduction of a Pneumococcal Conjugate Vaccine (PCV). PloS one. 2016;11(2):e0149104.
22. von Gottberg A, de Gouveia L, Tempia S, Quan V, Meiring S, von Mollendorf C, et al. Effects of vaccination on invasive pneumococcal disease in South Africa. The New England journal of medicine. 2014;371(20):1889-99.
23. MacLennan CA, Richter A, Hodson J, Faustini S, Birtwistle J, Whitelegg A, et al. Brief Report: Immunization of HIV-Infected Adults in the UK With Haemophilus influenzae b/Meningococcal C Glycoconjugate and Pneumococcal Polysaccharide Vaccines. Journal of acquired immune deficiency syndromes. 2016;73(3):287-93.
24. French N, Nakiyingi J, Carpenter LM, Lugada E, Watera C, Moi K, et al. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet. 2000;355(9221):2106-11.
25. Sadlier C, O'Dea S, Bennett K, Dunne J, Conlon N, Bergin C. Immunological efficacy of pneumococcal vaccine strategies in HIV-infected adults: a randomized clinical trial. Scientific reports. 2016;6:32076.
26. Jones N, Huebner R, Khoosal M, Crewe-Brown H, Klugman K. The impact of HIV on Streptococcus pneumoniae bacteraemia in a South African population. Aids. 1998;12(16):2177-84.
27. Lee KY, Tsai MS, Kuo KC, Tsai JC, Sun HY, Cheng AC, et al. Pneumococcal vaccination among HIV-infected adult patients in the era of combination antiretroviral therapy. Human vaccines & immunotherapeutics. 2014;10(12):3700-10.
28. Geretti AM, Brook G, Cameron C, Chadwick D, French N, Heyderman R, et al. British HIV Association Guidelines on the Use of Vaccines in HIV-Positive Adults 2015. HIV medicine. 2016;17 Suppl 3:s2-s81.
29. Iyer AS, Leggat DJ, Ohtola JA, Duggan JM, Georgescu CA, Al Rizaiza AA, et al. Response to Pneumococcal Polysaccharide Vaccination in HIV-Positive Individuals on Long Term Highly Active Antiretroviral Therapy. Journal of AIDS & clinical research. 2015;6(2).
30. MacNeil JR, Rubin LG, Patton M, Ortega-Sanchez IR, Martin SW. Recommendations for Use of Meningococcal Conjugate Vaccines in HIV-Infected Persons - Advisory Committee on Immunization Practices, 2016. MMWR Morbidity and mortality weekly report. 2016;65(43):1189-94.
31. Miller L, Arakaki L, Ramautar A, Bodach S, Braunstein SL, Kennedy J, et al. Elevated risk for invasive meningococcal disease among persons with HIV. Annals of internal medicine. 2014;160(1):30-7.
32. Harris CM, Wu HM, Li J, Hall HI, Lee A, Zell E, et al. Meningococcal Disease in Patients With Human Immunodeficiency Virus Infection: A Review of Cases Reported Through Active Surveillance in the United States, 2000-2008. Open forum infectious diseases. 2016;3(4):ofw226.
33. Cohen C, Singh E, Wu HM, Martin S, de Gouveia L, Klugman KP, et al. Increased incidence of meningococcal disease in HIV-infected individuals associated with higher case-fatality ratios in South Africa. Aids. 2010;24(9):1351-60.
34. Jafri RZ, Ali A, Messonnier NE, Tevi-Benissan C, Durrheim D, Eskola J, et al. Global epidemiology of invasive meningococcal disease. Population health metrics. 2013;11(1):17.
35. Campos-Outcalt D. Practice Alert: ACIP vaccine update, 2017. J Fam Pract. 2017;66(3):166-9.
36. Khatami A, Pollard AJ. The epidemiology of meningococcal disease and the impact of vaccines. Expert review of vaccines. 2010;9(3):285-98.
37. Pertussis vaccines: WHO position paper - September 2015. Wkly Epidemiol Rec. 2015;90(35):433-58.
38. Nunes MC, Downs S, Jones S, van Niekerk N, Cutland CL, Madhi SA. Bordetella pertussis Infection in South African HIV-Infected and HIV-Uninfected Mother-Infant Dyads: A Longitudinal Cohort Study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2016;63(suppl 4):S174-S80.
39. Celentano LP, Massari M, Paramatti D, Salmaso S, Tozzi AE, Group E-N. Resurgence of pertussis in Europe. The Pediatric infectious disease journal. 2005;24(9):761-5.
40. Troy SB, Rossheim AE, Hilliard DD, Cunningham TD. Brief Report: Seroprevalence of Pertussis Infection in HIV-Infected Adults in the United States. Journal of acquired immune deficiency syndromes. 2016;73(3):282-6.
41. Ward JI, Cherry JD, Chang SJ, Partridge S, Keitel W, Edwards K, et al. Bordetella Pertussis infections in vaccinated and unvaccinated adolescents and adults, as assessed in a national prospective randomized Acellular Pertussis Vaccine Trial (APERT). Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2006;43(2):151-7.
42. Dangor Z, Nunes MC, Kwatra G, Lala SG, Madhi SA. Vaccination of HIV-infected pregnant women: implications for protection of their young infants. Trop Dis Travel Med Vaccines. 2017;3:1.
43. Kroon FP, van Dissel JT, Labadie J, van Loon AM, van Furth R. Antibody response to diphtheria, tetanus, and poliomyelitis vaccines in relation to the number of CD4+ T lymphocytes in adults infected with human immunodeficiency virus. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 1995;21(5):1197-203.
44. Rosenblatt HM, Song LY, Nachman SA, Stanley KE, Krogstad PA, Johnson GM, et al. Tetanus immunity after diphtheria, tetanus toxoids, and acellular pertussis vaccination in children with clinically stable HIV infection. The Journal of allergy and clinical immunology. 2005;116(3):698-703.
45. Mena G, Garcia-Basteiro AL, Bayas JM. Hepatitis B and A vaccination in HIV-infected adults: A review. Human vaccines & immunotherapeutics. 2015;11(11):2582-98.
46. Franco E, Meleleo C, Serino L, Sorbara D, Zaratti L. Hepatitis A: Epidemiology and prevention in developing countries. World J Hepatol. 2012;4(3):68-73.
47. Beebeejaun K, Degala S, Balogun K, Simms I, Woodhall SC, Heinsbroek E, et al. Outbreak of hepatitis A associated with men who have sex with men (MSM), England, July 2016 to January 2017. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin. 2017;22(5).
48. Cheng A, Chang SY, Sun HY, Tsai MS, Liu WC, Su YC, et al. Long-term durability of responses to 2 or 3 doses of hepatitis A vaccination in HIV-positive adults on antiretroviral therapy. The Journal of infectious diseases. 2016.
49. Catherine FX, Piroth L. Hepatitis B virus vaccination in HIV-infected people: a review. Human vaccines & immunotherapeutics. 2017:1-10.
50. Amponsah-Dacosta E, Rakgole JN, Gededzha MP, Lukhwareni A, Blackard JT, Selabe SG, et al. Evidence of susceptibility to lamivudine-based HAART and genetic stability of hepatitis B virus (HBV) in HIV co-infected patients: A South African longitudinal HBV whole genome study. Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases. 2016;43:232-8.
51. Stabinski L, O'Connor S, Barnhart M, Kahn RJ, Hamm TE. Prevalence of HIV and hepatitis B virus co-infection in sub-Saharan Africa and the potential impact and program feasibility of hepatitis B surface antigen screening in resource-limited settings. Journal of acquired immune deficiency syndromes. 2015;68 Suppl 3:S274-85.
52. Burnett RJ, Kramvis A, Dochez C, Meheus A. An update after 16 years of hepatitis B vaccination in South Africa. Vaccine. 2012;30 Suppl 3:C45-51.
53. Amponsah-Dacosta E, Lebelo RL, Rakgole JN, Burnett RJ, Selabe SG, Mphahlele MJ. Evidence for a change in the epidemiology of hepatitis B virus infection after nearly two decades of universal hepatitis B vaccination in South Africa. Journal of medical virology. 2014;86(6):918-24.
54. Publication WHO. Hepatitis B vaccines: WHO position paper--recommendations. Vaccine. 2010;28(3):589-90.
55. Landrum ML, Huppler Hullsiek K, Ganesan A, Weintrob AC, Crum-Cianflone NF, Barthel RV, et al. Hepatitis B vaccine responses in a large U.S. military cohort of HIV-infected individuals: another benefit of HAART in those with preserved CD4 count. Vaccine. 2009;27(34):4731-8.
56. Crum-Cianflone NF, Sullivan E. Vaccinations for the HIV-Infected Adult: A Review of the Current Recommendations, Part I. Infect Dis Ther. 2017.
57. Hepatitis B vaccines: WHO position paper - July 2017. Wkly Epidemiol Rec. 2017;92(27):369-92.
58. Ni JD, Xiong YZ, Wang XJ, Xiu LC. Does increased hepatitis B vaccination dose lead to a better immune response in HIV-infected patients than standard dose vaccination: a meta-analysis? International journal of STD & AIDS. 2013;24(2):117-22.
59. Potsch DV, Oliveira ML, Ginuino C, Miguel JC, Oliveira SA, Silva EF, et al. High rates of serological response to a modified hepatitis B vaccination schedule in HIV-infected adults subjects. Vaccine. 2010;28(6):1447-50.
60. Kojic EM, Rana AI, Cu-Uvin S. Human papillomavirus vaccination in HIV-infected women: need for increased coverage. Expert review of vaccines. 2016;15(1):105-17.
61. Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, et al. Comprehensive control of human papillomavirus infections and related diseases. Vaccine. 2013;31 Suppl 7:H1-31.
62. Heard I. Human papillomavirus, cancer and vaccination. Current opinion in HIV and AIDS. 2011;6(4):297-302.
63. Denny L, Hendricks B, Gordon C, Thomas F, Hezareh M, Dobbelaere K, et al. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study. Vaccine. 2013;31(48):5745-53.
64. Romanowski B, Schwarz TF, Ferguson LM, Peters K, Dionne M, Schulze K, et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study. Human vaccines. 2011;7(12):1374-86.
65. Garland SM, Kjaer SK, Munoz N, Block SL, Brown DR, DiNubile MJ, et al. Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2016;63(4):519-27.
66. Chitsike I, van Furth R. Paralytic poliomyelitis associated with live oral poliomyelitis vaccine in child with HIV infection in Zimbabwe: case report. Bmj. 1999;318(7187):841-3.
67. Vardinon N, Handsher R, Burke M, Zacut V, Yust I. Poliovirus vaccination responses in HIV-infected patients: correlation with T4 cell counts. The Journal of infectious diseases. 1990;162(1):238-41.
68. Rivas P, Herrero MD, Puente S, Ramirez-Olivencia G, Soriano V. Immunizations in HIV-infected adults. AIDS reviews. 2007;9(3):173-87.
69. Kramer JM, LaRussa P, Tsai WC, Carney P, Leber SM, Gahagan S, et al. Disseminated vaccine strain varicella as the acquired immunodeficiency syndrome-defining illness in a previously undiagnosed child. Pediatrics. 2001;108(2):E39.
70. Maves RC, Tripp MS, Dell TG, Bennett JW, Ahluwalia JS, Tamminga C, et al. Disseminated vaccine-strain varicella as initial presentation of the acquired immunodeficiency syndrome: a case report and review of the literature. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology. 2014;59(1):63-6.
71. Singh HK, Chiu YL, Wilkin T. Measles, Mumps, and Rubella Serostatus and Response to MMR Vaccination Among HIV-Infected Adults. AIDS patient care and STDs. 2015;29(9):461-4.
72. Weinberg A, Levin MJ, Macgregor RR. Safety and immunogenicity of a live attenuated varicella vaccine in VZV-seropositive HIV-infected adults. Human vaccines. 2010;6(4):318-21.
73. Hussey HS, Abdullahi LH, Collins JE, Muloiwa R, Hussey GD, Kagina BM. Varicella zoster virus-associated morbidity and mortality in Africa: a systematic review protocol. BMJ open. 2016;6(4):e010213.
74. Shafran SD. Live attenuated herpes zoster vaccine for HIV-infected adults. HIV medicine. 2016;17(4):305-10.
75. Berkowitz EM, Moyle G, Stellbrink HJ, Schurmann D, Kegg S, Stoll M, et al. Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study. The Journal of infectious diseases. 2015;211(8):1279-87.
76. Benson CA HL, Anderson JW, Jiang JH, Bozzolo DR, Bergstrom K, Annunziato PW, Read SW, Pollard R, Rusin D, Lennox J. Zostavax® is Generally Safe and Immunogenic in HIV-Infected Adults with CD4 Counts ≥200 Cells/μL Virologically Suppressed on ART: Results of a Phase 2, Randomized, Placebo-Controlled Trial.  The 19th Conference on Retroviruses and Opportunistic Infections (CROI); March 5-8 2012; Seattle, WA2012.